About the CARE-MS
Studies
The Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis (CARE-MSSM)
I and II studies are designed to determine the safety and effectiveness of the investigational
drug alemtuzumab as compared to the FDA-approved therapy Rebif (interferon beta-1a),
in adults with relapsing-remitting multiple sclerosis (RRMS). The studies will look
for differences between these drugs on the progression of disability and in the
number of relapses (flare-ups) and brain lesions caused by MS. The studies also
will compare the side effects of the drugs and monitor for risks during and after
treatment.
Although CARE-MS I and II evaluate the same 2 therapies, the processes and criteria
of the studies are different.